NASDAQ:RNA Avidity Biosciences Q3 2026 Earnings Date & Estimates $8.20 0.00 (0.00%) As of 10/23/2026 04:00 PM Eastern Avidity Biosciences is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. The conference call is scheduled for November 13, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026Conference Call DateNovember 13, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Avidity Biosciences in Q3 2026Avidity Biosciences is expected to post earnings of -$0.8109 per share on revenue of $15.00 million. In the same quarter a year earlier Avidity Biosciences reported -$1.27 per share on revenue of $12.48 million. Avidity Biosciences last reported on August 13, 2026, posting -$1.18 per share and beating the -$1.42 consensus estimate. Avidity Biosciences has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.8109Expected Revenue$15.00 millionPrior-Year EPS-$1.27Prior-Year Revenue$12.48 millionExpected Revenue Growth+20.2%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$1.18 (Beat by +$0.24)Last Quarter Revenue$3.00 millionEPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Avidity Biosciences Q3 2026 Earnings FAQ When does Avidity Biosciences report Q3 2026 earnings? Avidity Biosciences (NASDAQ:RNA) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Avidity Biosciences' Q3 2026 earnings call? Avidity Biosciences' Q3 2026 earnings conference call is scheduled for Friday, November 13, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Avidity Biosciences? Analysts expect Avidity Biosciences to post earnings of -$0.8109 per share for Q3 2026. How much revenue is Avidity Biosciences expected to report? The consensus revenue estimate for Avidity Biosciences is $15.00 million for Q3 2026. Avidity Biosciences Earnings HeadlinesAvidity Biosciences (NASDAQ:RNA) Stock Picked Up by Analysts at Roth CapitalOctober 24 at 2:25 AM | americanbankingnews.comAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 20, 2026 | prnewswire.comTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years. | Porter & Company (Ad)Yakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive FinancingOctober 20, 2026 | prnewswire.comAvidity Biosciences, Inc. (RNA) - What Are Investment Firms Thinking About This Stock?October 19, 2026 | americanbankingnews.comAtrium Therapeutics Announces $50 Million Private PlacementOctober 8, 2026 | prnewswire.comSee More Avidity Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avidity Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your email. Email Address About Avidity BiosciencesAvidity Biosciences (NASDAQ:RNA) is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s approach is designed to address conditions that are difficult to treat with conventional oligonucleotide therapies, including diseases affecting skeletal muscle. Avidity’s proprietary AOC (antibody oligonucleotide conjugate) platform combines monoclonal antibodies with oligonucleotide-based medicines. The antibody component is intended to help deliver the therapeutic payload to specific tissues, while the oligonucleotide component is designed to modify or regulate disease-related RNA. The company’s research and development programs have included treatments for myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy and Duchenne muscular dystrophy. Founded in 2012 and headquartered in San Diego, California, Avidity became a publicly traded company in 2020. Its medicines are being developed through clinical and preclinical programs intended for patients in the United States and other international markets. Sarah Boyce serves as the company’s president and chief executive officer.View Avidity Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/19 - 10/23Amex Stock Slides on Job Cuts, But the Real Story Is MacroBloom Energy Just Reported—Its Biggest Order Is Still Waiting on a PipelineNewmont’s Record Quarter Shows Why Gold’s Floor Is the Real StoryLockheed Martin’s Record $292 Billion Backlog Comes With a Delivery TestCan Planet Fitness Get Its Growth Back in Shape?Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Upcoming Earnings Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026)ONEOK (10/27/2026)Robinhood Markets (10/27/2026)HSBC (10/27/2026)S&P Global (10/27/2026)Visa (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
